Polarean Imaging (LSE:POLX) has formalized a Representative Agreement with Ascend Imaging to promote and distribute its cutting-edge Xenon MRI platform across four US states. This collaboration is set to boost Polarean’s commercial presence and support its strategic growth ambitions in the competitive American healthcare market.

By tapping into Ascend Imaging’s radiology expertise and established customer base, Polarean aims to increase adoption of its innovative MRI technology designed for enhanced lung function visualization.

About Polarean Imaging

Polarean Imaging specializes in advanced medical imaging solutions with a focus on pulmonary health. Its flagship product, the FDA-cleared XENOVIEW®, utilizes hyperpolarized Xenon gas as a contrast agent to enable non-invasive, radiation-free lung MRI scans. The technology addresses the needs of over 500 million patients worldwide suffering from chronic respiratory conditions, representing a major advancement in pulmonary diagnostics.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.